January 2012 in “Chinese Clinical Oncology” Disodium folinate can safely and effectively replace calcium folinate in colorectal cancer treatment.
January 2008 in “Projeto: revista mensal de arquitetura” Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.
12 citations
,
May 2010 in “Journal of Clinical Oncology” MK-5108 is safe and shows potential against tumors, especially alone.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
21 citations
,
February 2013 in “Clinics in Dermatology” New treatments for advanced skin cancer are improving patient outcomes, but drug resistance and finding the right treatment combinations are still big challenges.
5 citations
,
March 2020 in “Thoracic Cancer” CT-707 is effective and safe for treating certain Chinese lung cancer patients.
1 citations
,
March 2019 in “Actas Dermo-Sifiliográficas” New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.
15 citations
,
March 2024 in “Journal of Clinical Medicine” Selumetinib causes skin and hair side effects in kids with NF1, affecting treatment and quality of life.
508 citations
,
June 2009 in “Current drug metabolism” Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
16 citations
,
March 2015 in “Clinical Cancer Research” The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.
8 citations
,
May 2019 in “Journal of dermatological treatment” Vismodegib is effective for basal cell carcinoma but has severe side effects.
21 citations
,
March 2015 in “Journal of The American Academy of Dermatology” Vemurafenib therapy can cause hair loss, but clobetasol propionate foam can help regrow hair.
25 citations
,
May 2018 in “Clinical & Translational Oncology” New melanoma treatments can cause skin side effects, including skin cancer and rashes, but combining treatments may reduce these risks.
Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.
1 citations
,
May 2025 in “BMC Cancer” CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.
16 citations
,
January 2017 in “Archives of Medical Science” Sorafenib after liver surgery may increase survival for some liver cancer patients.
March 2009 in “European Urology Supplements”
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
9 citations
,
December 2018 in “Cutaneous and Ocular Toxicology” Combined BRAF and MEK treatment increases rash risk but reduces other skin issues compared to BRAF alone.
54 citations
,
September 2012 in “Acta ophthalmologica” Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.
1 citations
,
January 2023 in “Bioscience Journal” Sorafenib and Platycladus orientalis leaf extract together effectively suppress cervical cancer cell growth.
1 citations
,
April 2010 in “Cancer Research” WYE-130600 may cause skin thickening and irritation.
November 2005 in “Reactions Weekly” A man treated with gefitinib for lung cancer grew new hair on his bald scalp.
28 citations
,
July 2017 in “Expert Review of Anticancer Therapy” Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
October 2024 in “Media Farmasi” Combining soursop leaf extract with doxorubicin may improve breast cancer treatment and reduce side effects.
February 2026 in “Molecules” BBR-SA nanomedicine is a safe and effective treatment for breast cancer.
8 citations
,
August 2018 in “BMJ Case Reports” Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.
1 citations
,
April 2023 in “Heliyon” Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
April 2016 in “Journal of Investigative Dermatology” MEK and BRAF inhibitors increase sebum production and accumulation, which could cause acne-like side effects.
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.